Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Regulatory press release

Integrum AB: Integrum's expansion in US continues with new Osseointegration Center at Emory Healthcare, Georgia

Integrum
Read the release

Patients at Emory Healthcare now have access to the OPRA™ Implant system for above-knee amputations.

Emory Healthcare (https://www.emoryhealthcare.org/), the largest healthcare system in the state of Georgia with 11 hospitals and 250 provider locations, has launched a new Osseointegration Program with Integrum's OPRA™ Implant System. The program is led by Nickolas Reimer, MD, (https://providers.emoryhealthcare.org/provider/Nickolas+Bernard+Reimer/780149) and Shervin Oskouei, MD (https://providers.emoryhealthcare.org/provider/Shervin+V+Oskouei/778866),  specialists in orthopaedic oncology and orthopaedic surgery.

Integrum's OPRA™ Implant System (https://integrum.se/opra-implant-system/) is the only FDA-approved, bone-anchored prosthetic solution available in the United States. OPRA™ Implant System consists of an anchorage element (fixture) and a skin penetrating device (abutment). The fixture is surgically inserted into the femur, and after a healing time of several months, the abutment is connected to the fixture. The prosthetic leg is then attached directly to the abutment via the OPRA™ Axor™, a prosthetic connection and safety device.

"We're excited to introduce this new technology to our patients to advance their limb function and improve their quality of life," says Scott D. Boden, MD (https://providers.emoryhealthcare.org/provider/Scott+D+Boden/779092), vice president for business innovation for Emory Healthcare and professor and chair of the Department of Orthopaedics, Emory University School of Medicine.

Over the past years, the introduction and consideration of osseointegration as a viable option for specific amputees within the limb loss community has continued to establish itself in the U.S. market. This rapidly developing treatment for amputee care gained a considerable boost when the FDA awarded Integrum an HDE approval for the OPRA™ Implant System in July 2015. The subsequent years have seen the Department of Defense, University of California San Francisco, Johns Hopkins Hospital, and Presbyterian St.Luke's Medical Center Hospital adopt the OPRA™ Implant System.

Blake Pokress, Vice President of Integrum Inc added, "We are excited to see Emory Healthcare adopt our technology through our partners at Onkos Surgical (https://onkossurgical.com/). We strive to make this remarkable technology accessible for individuals living with limb loss in the United States, and this is another step towards that".

To make an appointment at Emory Orthopaedics & Spine Center (https://www.emoryhealthcare.org/centers-programs/orthopedic-spine-center/index.html?utm_source=print&utm_campaign=default&utm_medium=short-url&utm_content=ortho), call 404-778-3350.

[image]

The information in this press release is information that Integrum AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the contact person set out below, at 14:30 CET on August 26[th], 2020.Integrum AB is listed on Nasdaq First North in Stockholm. Erik Penser is the Company's Certified Adviser.

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.